GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » Interest Coverage

PALI (Palisade Bio) Interest Coverage : 0 (At Loss) (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Palisade Bio's Operating Income for the three months ended in Mar. 2025 was $-2.31 Mil. Palisade Bio's Interest Expense for the three months ended in Mar. 2025 was $-0.00 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Palisade Bio's Interest Coverage or its related term are showing as below:


PALI's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Palisade Bio Interest Coverage Historical Data

The historical data trend for Palisade Bio's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Palisade Bio Interest Coverage Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Interest Coverage
- - - - -

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Palisade Bio's Interest Coverage

For the Biotechnology subindustry, Palisade Bio's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Palisade Bio's Interest Coverage falls into.


;
;

Palisade Bio Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Palisade Bio's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Palisade Bio's Interest Expense was $-0.01 Mil. Its Operating Income was $-14.86 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Palisade Bio did not have earnings to cover the interest expense.

Palisade Bio's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Here, for the three months ended in Mar. 2025, Palisade Bio's Interest Expense was $-0.00 Mil. Its Operating Income was $-2.31 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Palisade Bio did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Palisade Bio  (NAS:PALI) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Palisade Bio Interest Coverage Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio Business Description

Traded in Other Exchanges
N/A
Address
7750 El Camino Real, Suite 2A, Carlsbad, CA, USA, 92009
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley officer: Chief Financial Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones officer: Chief Medical Officer 70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae officer: Chief Operating Officer 675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam director, officer: Chief Executive Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson officer: Chief Medical Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center 10 percent owner 2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei director P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter director, officer: Executive Chairman 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma director 14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142

Palisade Bio Headlines

From GuruFocus